Navigation Links
Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
Date:5/2/2011

SAN DIEGO, May 2, 2011 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM152, the Company's oral selective antagonist of the LPA1 receptor.  Completion of this study positions Amira to initiate a Phase 2a study in patients suffering from systemic sclerosis, a systemic fibrotic disease, by early 2012.

"The Phase 1 clinical study in healthy volunteers demonstrated that AM152 is safe and well-tolerated at doses which are expected to provide a full range of receptor coverage in humans," said Isabelle DeArmond, Vice President, Clinical Development. "These results enable us to study AM152 at a wide range of doses in patients suffering from fibrotic diseases."

Bob Baltera, Chief Executive Officer, added, "Initiating a Phase 2a study in patients suffering from systemic sclerosis will be an important milestone for the team at Amira; we look forward to better understanding the potential therapeutic benefit of AM152."

AM152 is a novel LPA1 receptor antagonist developed by the scientists at Amira.  Preclinical data has demonstrated that antagonism of the LPA1 receptor inhibits fibrosis in several disease models.  Much of these data has been previously presented and published by Amira scientists and colleagues.  Amira Pharmaceuticals also recently announced that AM152 was granted Orphan Drug Status by the FDA for patients suffering from idiopathic pulmonary fibrosis (IPF).

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.  Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions.
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
2. Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
3. Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist
4. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
5. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
6. Visage Imaging Releases Amira 5.3
7. Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
8. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
9. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
10. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
11. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... ALBANY, New York , July 27, 2015 ... Transparency Market Research "Bionics Market - Global Industry Analysis, Size, ... market was valued at USD 7.96 billion in 2014, growing ... account for USD 20.49 billion in 2021. The ... in the number of accidents, which is leading to paralysis ...
(Date:7/27/2015)... , July 20, 2015 Research and ... of the "D-dimer Testing Market - Global ... Forecast 2014 - 2022" report to their ... vitro diagnostics market is one of the fastest ... attributed to the improved health care awareness, preference ...
(Date:7/27/2015)... July 27, 2015 The Physician-Patient Alliance for Health ... PPAHS posted its first blog on July 27, 2011, " ... ". This post featured what happened to ... of a grocery store in Goodhue, Minnesota ... marathon involving 20 others, who took turns pumping his chest. ...
Breaking Medicine Technology:Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 2Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 3Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 4D-dimer Testing Market - Global Industry Analysis 2015 2D-dimer Testing Market - Global Industry Analysis 2015 3Physician-Patient Alliance for Health & Safety Turns 4 Years Old 2
... at American Society of Clinical Oncology 2009 Annual Meeting ... , , SAN FRANCISCO, June 2 Medivation, ... presentation of new clinical results from a Phase 1-2 ... castration-resistant prostate cancer (CRPC) patients. The new findings, ...
... , Panel Discussant Focuses on Longer Duration of Remission ... Complete Remissions Achieved with Standard Chemotherapy , , ... MTA: CTIC) announced today that at the poster and ... Section at the 2009 American Society of Clinical Oncology ...
Cached Medicine Technology:Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 2Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 3Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 4Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 5Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 2Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 3Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 4Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 5Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 6
(Date:7/28/2015)... ... 28, 2015 , ... Care to Care LLC is expanding ... system, called “Referral Guidance.” , Referral Guidance consists of conditions and ... making a subspecialty referral an efficient means to ensure the referral is appropriate, ...
(Date:7/28/2015)... Atlanta, GA (PRWEB) , ... July 28, 2015 , ... ... has been chosen as a “Top Doctor 2015” by Atlanta Magazine. In Atlanta Magazine's ... a row by hundreds of her esteemed colleagues and peers in the metro area ...
(Date:7/28/2015)... Hills, CA (PRWEB) , ... July 28, 2015 , ... ... Chamber Therapy May Easy Fibromyalgia, Study Says " sheds light on a possible new ... a period of two months of regular HBOT sessions, at least five per week, ...
(Date:7/28/2015)... ... July 28, 2015 , ... The PULs ... Sudden Death, or Angina), many of whom are missed by conventional evaluation ... with active yet undetected sub-clinical disease, who are at risk of experiencing a ...
(Date:7/28/2015)... ... July 28, 2015 , ... ... the 2015 NCW Eco-Excellence Award for the Nutrition Beverage category. Established by NCW ... and elevate companies that stand out for their social and environmental sustainability. , ...
Breaking Medicine News(10 mins):Health News:Introducing Care to Care’s New Web Based “Referral Guidance” Program 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 3Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 2Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 3Health News:Utility of a novel coronary artery disease biomarker algorithm in modifying physician adherence to guideline therapy presented at 20th World Congress on Heart Disease 2Health News:Coco Libre Wins 2015 NCW Eco-Excellence Award 2
... marked by African leaders to stress on the devastating effects malaria ... , Every day 3000 African children die, and a million ... as a continuation of last year’s efforts by Canadian MP Belinda ... poised to do more of that.,Under the motto "Ten bucks. One ...
... are inheritably couch potatoes. An overeating, slothful horse leads to ... see the dangers of an// obese horse. Caretakers may see ... in horses is just as unhealthy as obesity in humans ... is a striking parallelism between humans and horses when it ...
... to over-exploitation, will get help in protecting its green ... the// country as a member this month. ... - a non-governmental research organization that conducts studies on ... global change - has said it can chip in ...
... genetic disorders that weaken the muscles to such an ... the victim’s quality of life, while also reducing the ... disorder still remains a burning ambition for many scientists. ... of muscular dystrophy disorders. Sadly, almost 100 male children ...
... left in the hands of generals, so also the safety of ... At least such// seems to be the case in the US. ... Safety and Health Administration (OSHA) are more concerned with promoting ... workers themselves. ,Seven years ago, a Missouri ...
... increased rates of serious infections caused by strains ... the current childhood pneumococcal vaccine,// according to a ... conjugate vaccine (PCV7), Alaska Native children and adults ... compared with non–Native Alaskans. Introduction of PCV7 into ...
Cached Medicine News:Health News:Bed Nets - A Formidable Weapon Against Malaria In Africa 2Health News:Humans Aren't the Only Ones With Obesity Problems 2Health News:India to Protect Its Forests With the Aid of Austrian NGO 2Health News:Overseeing Agency Indifferent to Workplace Safety in US 2Health News:Increase in Pneumococcal Infections That are Not Covered by Vaccine 2
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 6 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 7.0 mm and length 7.7 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 6.0 mm and length 10 mm....
Medicine Products: